The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

With aging, the intestine gradually loses its ability to regenerate after damage. An international research team involving ...

A Singaporean research team has developed CAN-Scan (short for Cancer Scan), a next-generation precision oncology platform ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

AstraZeneca's (AZN.L, AZN.ST) Imfinzi was cleared in the US for use with chemotherapy to treat resectable, early-stage, and locally advanced gastric and gastroesophageal junction cancers, making it ...

Scientists at Northwestern University in Evanston, Illinois, have used nanotechnology to re-engineer the molecular structure ...

ASTRO's new guidelines enhance radiation therapy strategies for gastric cancer, improving treatment outcomes and patient care ...

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) was approved in the U.S. for the treatment of adult ...

Novocure announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure's Executive Chairman, ...

Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data ...